Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

  • End date
    Sep 30, 2022
  • participants needed
  • sponsor
    Korea University Guro Hospital
Updated on 23 January 2021


In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in patients with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy


This study is designed to be multi-center, open-label, single-arm, prospective, phase II trial of patient with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy. Approximately 69 patients will be enrolled into the trial, and expected study duration is 48 months from Institutional Review Board(IRB) and Korea Ministry of Food and Drug Safety(MFDS) approval date.

The study drug will be administered orally as one tablet(Gefitinib 250mg/ Erlotinib 150mg) once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug daily can be reduced according to dose reduction criteria in protocol. A cycle of study treatment is defined as 28 days, and subjects will visit the site every 2 cycles(56 days).

Condition EGFR Positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
Treatment EGFR, EGFR
Clinical Study IdentifierNCT03382795
SponsorKorea University Guro Hospital
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 19 yrs?
Gender: Male or Female
Do you have EGFR Positive Non-small Cell Lung Cancer?
Do you have any of these conditions: Do you have EGFR Positive Non-small Cell Lung Cancer??
Males or females 19 years of age
Non Small Cell Lung Cancer(Non-Squamous Cell Carcinoma) patients who had shown clinical benefits (Complete response(CR) or Partial response(PR) or Stable disease(SD) 6 months) from EGFR-TKIs as first line treatment and developed progressive disease, and then received cytotoxic chemotherapy more than 4 cycles and developed progressive disease, and then confirmed T790 negative and sensitizing EGFR mutation(E19Del, L858R, L861Q, G719X, E19insertion) positive in Histologic, cytologic specimen or blood
Patient with at least one measurable lesions according to RECIST v 1.1
Expected life expectancy 12 weeks
Eastern Cooperative Oncology Group(ECOG) performance status 2
Patients who have proper hematologic, renal and hepatic functions as follows
Absolute neutrophil count(ANC) 1,500/mm
platelets 100,000/mm
Hemoglobin 9g/dL
Total bilirubin 1.25 X UNL
Aspartate aminotransferase(AST or SGOT) and alanine aminotransferase(ALT or SGPT) 3.0 X UNL (if liver metastasis 5.0 X UNL)
Alkaline phosphatase 2.5 X UNL (if liver metastasis 5.0 X UNL)
Serum creatinine 1.5mg/dL
patients who are willing to comply with study procedure and voluntarily provide informed consent with signature

Exclusion Criteria

Patients who have preexisting or coexisting malignancies in other parts except for effectively treated non-melanoma skin cancer, cervical carcinoma in situ(CIS) cervical cancer within the last 5 years
Patients with brain metastasis except for the followings
Asymptomatic and stable brain metastases for which local treatment has been given: corticosteroids treatment isn't requiured for at least 2 weeks before starting the study treatment
Patients currently receiving palliative radiation therapy or have toxicities from radiation therapy at screening
Patients with clinically active history of interstitial lung disease(ILD), Drug induced ILD, Radiation pneumonitis
Patients with clinically significant cardiovascular disease or myocardial infarction within the past 12 months
Patients with active infection or severe systemic disease that are difficult to include in this study
Patients who received radiation therapy to target lesion of this study
Patients who had major operation within 4 weeks before starting the study treatment and were not fully recovered
Patients who were administered other study drugs within 4 weeks before starting the study treatment
Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive pregnancy test prior to study entry
Patients who are difficult to include in this study in accordance with the investigator's judgment
Patients with histories of hypersensitivity to investigational product(IP) or any components of the agent
Patients with any of the following genetic predispositions including galactose intolerance, Lapp lactase deficiency, lactose intolerance or glucose-galactose malabsorption
Patient previously received cytotoxic chemotherapy within 2 weeks of IP administration
Patient received Immunotherapy prior to the study participation
Patients who are difficult to include in this study in accordance with the investigator's judgment due to severe adverse effects during previous EGFR TKI treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note